Dr. Reddy’s Laboratories, a leading multinational pharmaceutical company based in India and overseas, committed to providing affordable and innovative medicines for healthier lives.
Dr Reddy's Laboratories is expecting its business growth to be "volatile" in the current fiscal, the company said in its Annual Report for 2020-21. "The last few months have seen a second wave of Covid-19 impacting several parts of the world, and the most in India. While vaccinations ...
Dr Reddy's Laboratories Ltd announced the launch of capecitabine tablets, USP a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (FDA). The Xeloda brand and generic had US sales of approximately $90 million MAT for the most r...
在该公司发布的最新财报中,公司每股收益为$0.20,总营收为$966.68M,而此前英为财情Investing.com对分析师的调查显示,分析师预期该公司的营收为$986.75M,每股收益为$0.22. 在Dr. Reddy’s Labs ADR公布财报前,本月还有一些医疗保健行业的美股公司也公布了财报。 1月16日 联合健康发布了第四季度的财报,其每股收益...
Beyond betapharm ; Dr Reddy's Labs has learnt plenty from a global acquisition that went spectacularly awry. Just one of those lessons: Build depth before ... EK Sharma 被引量: 0发表: 0年 Dr Reddy's Global Strides — Will the Success Story Continue? In February 2006, Dr Reddy's ...
1,201.40+15.25+1.29% 30/01- 闭盘. 类型:股票期货 市场:印度 相关:Dr Reddy’s Laboratories 昨收:1,191.60 开盘:1,189.65 当日幅度:1,186.40-1,210.95 REDYc2:NS历史数据 时间范围: 2024/12/30 - 2025/01/30 日期收盘开盘高低交易量涨跌幅
在Dr. Reddy’s Labs ADR公布财报前,本月还有一些医疗保健行业的美股公司也公布了财报。 1月16日 联合健康发布了第四季度的财报,其每股收益为$6.81,营收为 $100.8B , 华尔街对该公司的业绩预期为每股收益$6.74 , 营收为$101.61B. 此外,强生公司星期三发布的业绩报告超出了分析师的预期。数据显示,该公司的每股...
在Dr. Reddy’s Labs ADR公布财报前,本月还有一些医疗保健行业的美股公司也公布了财报。 1月16日 联合健康发布了第四季度的财报,其每股收益为$6.81,营收为 $100.8B , 华尔街对该公司的业绩预期为每股收益$6.74 , 营收为$101.61B. 此外,强生公司星期三发布的业绩报告超出了分析师的预期。数据显示,该公司的每股...
"Dr Reddy's 'Celevida' is formulated to have high protein, high fibre and slowly digested carbohydrates, which will support in managing the postprandial blood glucose response and satiety. The product contains high amount of plant protein that comes from soy, ragi and gram flours. The product ...
Dr Reddy's Laboratories Ltd has launched the US Food and Drug Administration (FDA) approved bupropion hydrochloride extended-release tablets, USP (SR), a therapeutically equivalent generic version of Zyban. The Zyban brand and generic had US sales of approximately US$ 5.4 million MAT (moving annua...